NPM1 and acute myeloid leukemia: A new concept is also integrated: that of CR with detectable low-level MRD (CRMRD-LL), which refers to MRD < 2% and is equivalent to a negative MRD for NPM1 and CBF-AML as it is associated with a very low risk of relapse.